Literature DB >> 16813535

A novel mutation (K378X) in the sequestosome 1 gene associated with increased NF-kappaB signaling and Paget's disease of bone with a severe phenotype.

Sarah L Rea1, John P Walsh, Lynley Ward, Kirk Yip, Bryan K Ward, G Neil Kent, James H Steer, Jiake Xu, Thomas Ratajczak.   

Abstract

UNLABELLED: Sequestosome 1/p62 (p62) mutations are associated with PDB; however, there are limited data regarding functional consequences. We report a novel mutation in exon 7 (K378X) in a patient with polyostotic Paget's disease of bone. p62 mutants increased NF-kappaB activation and significantly potentiated osteoclast formation and bone resorption in human primary cell cultures.
INTRODUCTION: Sequestosome 1/p62 (p62) mutations are associated with Paget's disease of bone (PDB); however, there are limited data regarding functional consequences. One report has linked the common P392L mutation in the p62 ubiquitin binding associated (UBA) domain with increases in NF-kappaB activity, a transcription factor essential for osteoclastogenesis. To further clarify the functional impact of p62 mutations associated with PDB, we assessed the effect of p62 mutation (a novel mutation: K378X, and previously reported mutations: P392L and E396X) on RANK-induced NF-kappaB activation and compared this with the effect of wildtype p62. In addition, we studied the effect of p62 mutation on osteoclast formation and bone resorption.
MATERIALS AND METHODS: We performed co-transfection experiments with expression plasmids for p62 (wildtype or mutated) and RANK and an NF-kappaB luciferase reporter gene. Luciferase activities were recorded after addition of luciferin to cellular lysates. RAW(264.7) cells stably expressing enhanced green fluorescent protein (EGFP)-tagged p62 (wildtype, K378X, or P392L) or EGFP alone were assessed for changes in cell proliferation. Additionally, these cells were stimulated with RANKL to produce osteoclast-like cells (OLCs). Primary human monocytes collected from the K378X-affected patient and a control subject were stimulated to form OLCs and bone resorption data were obtained.
RESULTS: The novel mutation introduces a premature stop codon in place of Lys-378 and thereby eliminates the entire p62 UBA domain; this and two additional natural mutations (P392L, E396X) increased NF-kappaB activation compared with wildtype p62. Wildtype p62 consistently inhibited NF-kappaB activation compared with empty vector. UBA mutations (K378X and P392L) significantly increased the number of OLCs formed in response to RANKL and also the number of nuclei of the OLCs. K378X-affected human monocytes formed more OLCs with more nuclei and increased bone resorption compared with control monocytes.
CONCLUSIONS: Our data show that mutation of the p62 UBA domain results in increased activation of NF-kappaB and osteoclast formation and function compared with wildtype p62. These results may partially explain the mechanism by which p62 mutation contributes to the pathogenesis of PDB.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16813535     DOI: 10.1359/jbmr.060405

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  23 in total

1.  The majority of the genetic risk for Paget's disease of bone is explained by genetic variants close to the CSF1, OPTN, TM7SF4, and TNFRSF11A genes.

Authors:  Pui Yan Jenny Chung; Greet Beyens; Steven Boonen; Socrates Papapoulos; Piet Geusens; Marcel Karperien; Filip Vanhoenacker; Leon Verbruggen; Erik Fransen; Jan Van Offel; Stefan Goemaere; Hans-Georg Zmierczak; René Westhovens; Jean-Pierre Devogelaer; Wim Van Hul
Journal:  Hum Genet       Date:  2010-09-14       Impact factor: 4.132

2.  Paget's disease: epidemiology and pathophysiology.

Authors:  Margaret Seton
Journal:  Curr Osteoporos Rep       Date:  2008-12       Impact factor: 5.096

3.  Loss of WDFY3 ameliorates severity of serum transfer-induced arthritis independently of autophagy.

Authors:  Dennis J Wu; Iannis E Adamopoulos
Journal:  Cell Immunol       Date:  2017-04-22       Impact factor: 4.868

4.  Mutant p62P392L stimulation of osteoclast differentiation in Paget's disease of bone.

Authors:  Kumaran Sundaram; Srinivasan Shanmugarajan; D Sudhaker Rao; Sakamuri V Reddy
Journal:  Endocrinology       Date:  2011-08-30       Impact factor: 4.736

5.  Thirteen Chinese patients with sporadic Paget's disease of bone: clinical features, SQSTM1 mutation identification, and functional analysis.

Authors:  Jie-Mei Gu; Zhen-Lin Zhang; Hao Zhang; Wei-Wei Hu; Chun Wang; Hua Yue; Yao-Hua Ke; Jin-Wei He; Yun-Qiu Hu; Miao Li; Yu-Juan Liu; Wen-Zhen Fu
Journal:  J Bone Miner Metab       Date:  2012-04-11       Impact factor: 2.626

6.  p62/sequestosome 1 deficiency accelerates osteoclastogenesis in vitro and leads to Paget's disease-like bone phenotypes in mice.

Authors:  Frank Zach; Franziska Polzer; Alexandra Mueller; André Gessner
Journal:  J Biol Chem       Date:  2018-03-19       Impact factor: 5.157

7.  A quest for clarity in bone erosion: The role of sequestosome 1 in Paget's disease of bone.

Authors:  Megan N Michalski; Bart O Williams
Journal:  J Biol Chem       Date:  2018-06-15       Impact factor: 5.157

8.  Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice.

Authors:  Wei Jin; Mikyoung Chang; Emmanuel M Paul; Geetha Babu; Andrew J Lee; William Reiley; Ato Wright; Minying Zhang; Jun You; Shao-Cong Sun
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

9.  The p62 P392L mutation linked to Paget's disease induces activation of human osteoclasts.

Authors:  Estelle Chamoux; Julie Couture; Martine Bisson; Jean Morissette; Jacques P Brown; Sophie Roux
Journal:  Mol Endocrinol       Date:  2009-07-09

10.  Mutations within the TNF-like core domain of RANKL impair osteoclast differentiation and activation.

Authors:  Taksum Cheng; Nathan J Pavlos; Cathy Wang; Jamie We-Yin Tan; Jian Ming Lin; Jillian Cornish; Ming-Hao Zheng; Jiake Xu
Journal:  Mol Endocrinol       Date:  2008-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.